KIM
IART icon

Kestrel Investment Management’s Integra LifeSciences IART Stock Holding History

Kestrel Investment Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-99,350
Closed -$2.9M – 42
2024
Q2 		$2.9M Hold
99,350
– – 1.92% 23
2024
Q1 		$3.52M Sell
99,350
-700
-0.7% -$28K 2.35% 17
2023
Q4 		$4.36M Sell
100,050
-22,400
-18% -$882K 2.95% 15
2023
Q3 		$4.68M Buy
+122,450
New +$5.15M 2.96% 15

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kestrel Investment Management's IART Position: Q3 2024 in Review

Kestrel Investment Management sold out of Integra LifeSciences (IART) in Q3 2024, closing a stake of 99,350 shares — an estimated $2.9M sold.

Kestrel Investment Management first reported a position in IART in Q3 2023 and held it in 4 quarters. The position peaked at $4.68M in Q3 2023. 225 funds tracked by Wall St. Rank hold IART as of Q3 2024.

  • Kestrel Investment Management reported no remaining Integra LifeSciences position as of Q3 2024 after selling out during the quarter.
  • Kestrel Investment Management sold 99,350 Integra LifeSciences shares in Q3 2024, an estimated $2.9M.
  • Kestrel Investment Management first reported a position in Integra LifeSciences in Q3 2023 and held it in 4 quarters.
  • Kestrel Investment Management's Integra LifeSciences position peaked at $4.68M in Q3 2023.
  • 225 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2024.

Based on Kestrel Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.